{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-24-000059","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2024-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.177736+00:00","generated_at":"2026-05-31T22:24:08.502841+00:00","sec_items":["1.01","2.03"],"event_type":"debt","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Ligand ups revolving credit line to $125M from $75M","bullets":["First amendment to Oct 2023 Credit Agreement executed July 8, 2024, increasing aggregate revolving commitments from $75M to $125M.","Borrowing capacity expanded by $50M; no other material changes detailed in the filing.","Credit facility includes subsidiaries as guarantors; Citibank remains administrative agent, swingline lender and L/C issuer."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-24-000059","json":"https://secwatch.observer/filing/0000886163-24-000059.json","markdown":"https://secwatch.observer/filing/0000886163-24-000059.md","text":"https://secwatch.observer/filing/0000886163-24-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000059/0000886163-24-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000059/lgnd-20240708.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:24:08.502841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}